Bicara Therapeutics

formerly BicaraIPO

Fighting cancer with precision and power.

Public · Cambridge, United States · Founded 2020 · $313.0M raised

Employees
51–200
Founded
2020
Business Model
B2B
Total Funding
$313.0M
Last Round
$165.0M Series CDec 2023
Rounds
3
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class bifunctional biologics that combine tumor-targeting antibodies with tumor microenvironment modulators to treat solid tumors. Its bifunctional antibody platform is designed to deliver immunomodulatory payloads directly to the tumor site, enabling synergistic anti-tumor immune activity. The company is publicly traded (Nasdaq: BCAX) and advancing its lead programs through Phase 1b and Phase 3 clinical trials.

Summary

Bicara Therapeutics is a Biotech company based in Cambridge, United States, founded in 2020. It has raised $313.0M in total across 3 rounds, most recently a $165.0M Series C round in Dec 2023. Investors include Red Tree Venture Capital, RA Capital Management and Biocon Limited.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Secondary MarketPublic OfferingFeb 2026

Sign up to see all 5 events

Funding: Seed through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Bicara Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/bicara-therapeutics"><img src="https://indexed.vc/api/badge/company/bicara-therapeutics" alt="Bicara Therapeutics on Indexed.vc" width="260" height="76" /></a>